Melatonin Improves Levels of Zn and Cu in the Muscle of Diabetic Obese Rats by Navarro Alarcón, Miguel et al.
pharmaceutics
Article
Melatonin Improves Levels of Zn and Cu in the Muscle of
Diabetic Obese Rats
Miguel Navarro-Alarcón 1,* , Fernando Gil-Hernández 2 , Cristina Sánchez-González 3 , Juan Llopis 3 ,
Marina Villalón-Mir 1, Pablo Olmedo 2, Pablo Alarcón-Guijo 4,5 , Diego Salagre 4,5 , Lorena Gaona 4,5,6,





C.; Llopis, J.; Villalón-Mir, M.;
Olmedo, P.; Alarcón-Guijo, P.; Salagre,
D.; Gaona, L.; Paredes, M.; et al.
Melatonin Improves Levels of Zn and
Cu in the Muscle of Diabetic Obese
Rats. Pharmaceutics 2021, 13, 1535.
https://doi.org/10.3390/
pharmaceutics13101535
Academic Editor: Giovanna Rassu
Received: 25 August 2021
Accepted: 20 September 2021
Published: 22 September 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Nutrition and Bromatology, School of Pharmacy, University of Granada,
18016 Granada, Spain; marinavi@ugr.es
2 Department of Toxicology, School of Medicine, University of Granada, 18071 Granada, Spain;
fgil@ugr.es (F.G.-H.); polmedopalma@ugr.es (P.O.)
3 Department of Physiology, Institute of Nutrition and Food Science, Biomedical Research Centre, University of
Granada, 18071 Granada, Spain; crissg@ugr.es (C.S.-G.); jllopis@ugr.es (J.L.)
4 Department of Pharmacology, Biohealth Institute and Neurosciences Institute, School of Medicine, University
of Granada, 18016 Granada, Spain; palarcon@ugr.es (P.A.-G.); dsalagre@ugr.es (D.S.);
lgaona1972@hotmail.es (L.G.); md.marioparedes@gmail.com (M.P.)
5 Biohealth Research Institute in Granada (ibs. GRANADA), University Hospital of Granada,
18016 Granada, Spain
6 Department of Teaching of the Nursing Career of the Catholic University of Santiago de Guayaquil, General
Teaching Coordination Hospital of Specialties Dr. Teodoro Maldonado Carbo of Ecuador,
Guayaquil 090615, Ecuador
7 Department of Docent, Faculty of Medicine, Catholic University of Santiago de Guayaquil, Epidemiology and
Tropical Medicine Services, Directorate of Naval Health, Navy of Ecuador, Guayaquil 090615, Ecuador
* Correspondence: nalarcon@ugr.es (M.N.-A.); aagil@ugr.es (A.A.)
Abstract: Melatonin improves metabolic alterations associated with obesity and its diabetes (di-
abesity). We intend to determine whether this improvement is exerted by changing Zn and/or
Cu tissue levels in liver, muscle, pancreas, and brain, and in internal (perirenal, perigonadal, and
omentum) and subcutaneous lumbar white adipose tissues (IWAT and SWAT, respectively). Male
Zücker diabetic fatty (ZDF) rats and lean littermates (ZL) were orally supplemented either with
melatonin (10 mg/kg body weight/day) or vehicle for 6 weeks. Zn and Cu concentrations were not
significantly influenced by diabesity in the analyzed tissues (p > 0.05), with the exception of Zn in
liver. In skeletal muscle Zn and Cu, and in perirenal WAT, only Zn levels increased significantly
with melatonin supplementation in ZDF rats (p < 0.05). This cytoplasmic Zn enhancement would
be probably associated with the upregulation of several Zn influx membrane transporters (Zips)
and could explain the amelioration in the glycaemia and insulinaemia by upregulating the Akt and
downregulating the inhibitor PTP1B, in obese and diabetic conditions. Enhanced Zn and Cu levels in
muscle cells could be related to the reported antioxidant melatonin activity exerted by increasing the
Zn, Cu-SOD, and extracellular Cu-SOD activity. In conclusion, melatonin, by increasing the muscle
levels of Zn and Cu, joined with our previously reported findings improves glycaemia, insulinaemia,
and oxidative stress in this diabesity animal model.
Keywords: melatonin; zinc; copper; diabetic obese rat; muscle and other organ and white adipose tissues
1. Introduction
Melatonin is a potent antioxidant, and its presence in numerous plants and foods has
been described as beneficial to human health [1]. Melatonin is also a hormone synthesized
in multiple organs such as the pineal gland, which functions during the night period and
regulates the circadian rhythm [2,3]. It has been indicated that the decrease of endogenous
melatonin levels is associated with the increased risk of obesity, and the associated dia-
betes mellitus [4–8]. Moreover, it has been reported that Zn has an important role in the
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endogenous melatonin synthesis in the pineal gland [9]. On the other hand, the increase of
visceral white adipose tissue produces insulin resistance which affects skeletal muscle and
liver metabolism [10–13], eventually producing chronic hyperglycemia [3].
In several studies, Zn has been described to act insulin-likely in skeletal muscle
cells. It has been found that this activity is associated with the families of the differ-
ent Zn transporters [14,15], which are responsible for its traffic through biological mem-
branes [16], as well as metallothioneins that link it at the intracellular level [14]. These
researchers [15] reported that Zn administration stimulated glucose oxidation and glycemic
control by modulating the insulin signaling pathway in human and mouse skeletal muscle
cell lines. Similarly, Lu et al. [17] demonstrated that protamine Zn insulin combined with
sodium selenite improved glycometabolism in T2DM via upregulating phosphatidylinosi-
tol 3-kinase (PI3K), downregulating the protein tyrosine phosphatase 1B (PTP1B: Inhibitor
of the insulin receptor substrates 1 and 2 [Irs1 and Irs2]), reducing oxidative stress, and
ameliorating skeletal muscle and β-cell damage, as well as mitochondrial dynamics.
In relation to Cu, it has been reported that disturbances in their levels in several
organs and biofluids are correlated with abnormalities implicated in metabolic pathways
of diabetes and its complications [18,19]. Zhou et al. [20] reported that in a type 1 diabetic
mice model induced by streptozotozin, the renal and serum Cu levels were significantly
higher, while the hepatic Cu and Zn levels were significantly decreased at 2 weeks and
2 months, respectively, after the diabetes onset.
On the other hand, in T2DM, there is a marked meta-inflammation and oxidative
stress, which has been related to decreased expression and activity of cytoplasmic (Zn,
Cu-SOD: SOD1), mitochondrial (Mn-SOD: SOD2), and extracellular (Cu-SOD: SOD3)
superoxide dismutase (SOD) enzyme, an effect observed in different tissues such as liver,
skeletal muscle or kidney of diabetic animal models [17,21–24]. Among the multiple
pathways through which melatonin could exert its antioxidant effect, as described by Zhan
and Zhang [25], the activation of the SOD1 and SOD2 antioxidant enzymes is indicated,
or even, the reactivation of these enzymes in different animals as well as pathological
conditions [25–27].
In multiple studies on melatonin supplementation, this indolamine has been reported
to limit obesity, improve chronic hyperglycemia, and reverse the problems of glucose
intolerance, insulin resistance, oxidative stress, and inflammation [3,10,26–33]. However,
whether the positive effect that melatonin supplementation has been shown to exert on
blood glucose levels [3], insulinaemia [34], and oxidative stress [26] under conditions of
obesity and associated diabetes, is established through an intermediate signaling pathway
mediated by Zn and/or Cu levels in several tissues such as liver, muscle, pancreas, brain or
WAT, has not been done so far. Therefore, the aim of the present work is to study the possible
influence of melatonin supplementation on Zn and Cu levels in liver, muscle, pancreas, and
brain, and in internal (perirenal, perigonadal, and omentum) and subcutaneous lumbar
white adipose tissues (IWAT and SWAT, respectively) of an animal model of obesity and
associated T2DM (ZDF rats). Therefore, our study provides new insight into the possible
signaling pathways through which melatonin supplementation could exert the beneficial
effects described [35] in conditions of obesity and diabetes [2].
2. Experimental Section
2.1. Reagents
Melatonin was obtained from Sigma Chemicals Madrid, Spain. Commercially avail-
able standard solutions of Zn and Cu (1000 mg/L; Tritisol, Merck, Darmstadt, Germany)
were used to prepare calibration graphs. All of the solutions were prepared from analytical
grade reagents (Suprapur, Merck): 65% HNO3, 65% HClO4. Double-distilled deionized
water with a specific resistivity of 18 mΩ/cm was used to prepare standards for calibration
and dilutions, and was obtained immediately before use by filtering distilled water through
a Milli-Q purifier (Millipore, Waters, Mildford, MA, USA).
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2.2. Animals and Experimental Protocols
The experiment was approved by the Ethical Committee of the University of Granada
(Granada, Spain) according to the European Union guidelines. The permit project number
is 409-2016-CEEA.
The experiment was performed on 40 Zucker male rats: 20 ZDF rats (a 2-type DM
model) weighing 180–200 g, and 20 ZL rats weighing 120–140 g. They were bought at
5 weeks old from Charles River Laboratories (Barcelona). The rats were fed with Purina
chow whose composition was: Carbohydrates (58.5%), fat (6.5%), proteins (23%), fiber (4%),
and ash (6.8%). Animals had the ready diet and tap water with “ad libitum” access [36]. The
diet was administrated for 6 weeks, and the proportion of food intake by groups ZDF/ZL
was approximately 2.5 times [37]. The animals were housed 3–4 rats/plastic cage and kept
under controlled 12 h light-dark cycle (lights were switched on at 07:00 h).
At the age of 6 weeks, the animals were randomly divided into four groups (n = 10 per
group): The non–supplemented control groups (C–ZDF and C–ZL) and the melatonin-
supplemented groups (M–ZDF and M–ZL). Melatonin was dissolved in a minimum volume
of absolute ethanol. Then, it was diluted to the final solution of 0.066% (w/v) in the drinking
water to yield a dose of 10 mg/kg body weight (bw) and was received daily for 6 weeks.
The animals in the non–supplemented control groups received the vehicle in the drinking
water at a comparable dose and supplementation duration. Fresh melatonin and vehicle
solutions were prepared every 2 days. Moreover, the melatonin dose was adjusted for body
weight over the entire period of the study [37], taking into consideration that every 2 days
the rats were weighed again and the corresponding adjustments were made. Water bottles
were covered with aluminum foil to protect from light, and the drinking fluid was changed
twice weekly.
At the end of the experiment, the animals were sacrificed by intraperitoneal admin-
istration of sodium phenobarbital (thiopental) anesthesia at 40 mg/kg dose. The liver,
muscle, pancreas, and brain were collected by surgical excision. Internal WAT fat pads
(omental, perigonadal, and perirenal fat) and lumbar subcutaneous fat were visually in-
spected and also collected by surgical excision. All of the tissues were washed thoroughly
in a saline solution and stored at −80 ◦C for further experiments.
2.3. Zn and Cu Determination by Flame Atomic Absorption Spectrometry (AAS)
A Perkin-Elmer 1110B double-beam atomic absorption spectrophotometer equipped
with a Zn or with a multi-element Cu hollow cathode lamp were used together (Perkin-
Elmer, Norwalk CT, USA). A thermostatic multiplace digestion block (Selecta, S.A., Barcelona,
Spain) was also employed.
The Zn and Cu levels in the studied tissues (liver, muscle, pancreas, brain, and perigo-
nadal, perirenal, omental, and lumbar subcutaneous fat) were determined by weighing
0.100–0.200 g of the samples in Pyrex glass tubes, adding 0.8 mL HNO3, heating at 80 ◦C
for 15 min, and then at 180 ◦C for 45 min. Next, 0.8 mL of an HNO3–HClO4 solution (4:1)
was added and they were heated at 200 ◦C for 90 min. The resulting digested solution was
then diluted to 2.5 mL with Milli-Q water and maintained in this state until analysis [38].
The Zn and Cu levels were determined by flame (direct aspiration) atomic absorp-
tion spectrometry. In an accuracy test, the Zn and Cu concentrations measured by this
method in the certified reference material (Contox Trace Serum Metal Control-A Level I,
Kaulson Laboratories Inc., NJ, USA [78.8 ± 4.3 and 91.8 ± 1.4 µg/dL], respectively) did
not significantly differ (p > 0.05) from the certified levels [80.0 ± 6.0 and 90.0 ± 7.5 µg/dL,
respectively]) [36].
2.4. Statistical Analysis
A statistical evaluation of the results was carried out using the computer software
Statistical Package for the Social Sciences (SPSS 23.0, Chicago, IL, USA). The results have
been expressed as arithmetic means ± standard error of the mean (SEM). The variance
analysis and post hoc Tukey test were used for the comparison among groups. The
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p < 0.05 was statistically significant and levels of significance were labeled on the figures
as follows: * p < 0.05; ** p < 0.01; *** p < 0.001.
3. Results
Figures 1 and 2 exhibit the Zn concentrations, found in liver (Figure 1A), skeletal
muscle (Figure 1B), pancreas (Figure 1C), and brain (Figure 1D) samples, and in IWAT
(perirenal, perigonadal, and omentum adipose tissues, Figure 2A–C, respectively) and
SWAT (Figure 2D), from Zucker diabetic fatty (ZDF) and their lean littermates (ZL) rats.
In the present study, we have measured Zn concentrations in tissues reported for both
rat groups (ZL and ZDF) after previous melatonin supplementation (melatonin groups:
M–ZL and M–ZDF) or without melatonin supplementation (control groups: C–ZL and
C–ZDF). The Zn concentrations did not significantly differ between C–ZL and C–ZDF rats
for most of the several studied tissues, indicating that element concentrations in them were
not significantly influenced by the obesity and T2DM pathologies. The only one exception
was found for liver Zn concentrations, which were significantly increased in C–ZDF when
compared with the C–ZL group (p = 0.041).




Figure 1. Influence of melatonin supplementation in Zn levels of different organ tissues in male 
Zücker lean and diabetic fatty rats. (A) Liver Zn. (B) Skeletal muscle Zn. (C) Pancreas Zn. (D) Brain 
Zn. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with melatonin; C–ZDF: Control 
diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with melatonin; ZL: Zücker lean 
rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of ratios of Zn levels. * p < 
0.05; ** p < 0.01; *** p < 0.001 (Tukey post hoc test). 
For perirenal WAT (Figure 2B) and brain (Figure 1D) Zn levels measured in ZDF rats 
treated with melatonin were significantly higher than those measured in both ZL rat 
groups (M-ZDF vs. C-ZL group, p < 0.05 for both organs; M-ZDF vs. M-ZL group, p < 0.001 
and p < 0.01, respectively). Moreover, Zn concentrations found in omentum WAT (Figure 
2C) for ZDF rats treated with melatonin were significantly higher than those measured 
for ZL rats also treated with melatonin (M-ZL vs. M-ZDF group; p < 0.05; Figure 2C). An-
other striking finding is that from the eight analyzed tissues, for five (liver, pancreas, 
brain, and perirenal and subcutaneous lumbar WAT), significantly higher Zn concentra-
tions were measured in the melatonin-treated ZDF rats when compared with those found 
in non-treated ZL rats (M-ZDF vs. C-ZL; p < 0.001 for liver and p < 0.05 for the remaining 
reported tissues). Moreover, Zn concentrations found in the brain (Figure 1D), and perire-
nal and omentum WAT (Figure 2B and 2C, respectively) for melatonin-treated ZDF were 
significantly higher than those found for melatonin-treated ZL rats (M-ZL vs. M-ZDF 
group; p < 0.01, p < 0.001, and p < 0.05, respectively). 
Figure 1. Influence of melatonin supplementation in Zn levels of dif erent organ tis ues in male
Zücker lean and diabetic fatty rats. (A) Liver Zn. (B) Skeletal muscle Zn. (C) Pancreas Zn. (D) Brain
Zn. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with melatonin; C–ZDF: Control
diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with melatonin; ZL: Zücker lean
rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of ratios of Zn levels. * p < 0.05;
** p < 0.01; *** p < 0.001 (Tukey post hoc test).
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Figure 2. Influence of melatonin supplementation in Zn levels of white adipose tissues (WAT) in 
male Zücker lean and diabetic fatty rats. (A) Gonadal WAT Zn. (B) Renal WAT Zn. (C) Omentum 
WAT Zn. (D) Subcutaneous Zn. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with 
melatonin; C–ZDF: Control diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with 
melatonin; ZL: Zücker lean rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of 
ratios of Zn levels. * p < 0.05; ** p < 0.01; *** p < 0.001 (Tukey post hoc test). 
Figures 3 and 4 depict the Cu concentrations, respectively, measured in the same or-
gans (Figure 3A,B,C,D, respectively) and WAT (Figure 4A,B,C,D, respectively) from the 
same animal groups. The Cu concentrations did not significantly differ between C-ZL and 
C-ZDF rats for any of the several studied tissues, indicating that element concentrations 
in them are not significantly influenced by the obesity and T2DM pathologies. 
For Cu, in ZDF rats, the supplementation with melatonin significantly increased con-
centrations only in the muscle (C-ZDF vs. M-ZDF; Figure 3B; p < 0.05). In addition, in the 
liver for both groups of ZDF rats significantly higher Cu concentrations than those meas-
ured in melatonin-treated ZL rats were found (M-ZL vs. C-ZDF and M-ZDF; Figure 3A; p 
< 0.001 and p < 0.01, respectively). Moreover, in the liver Cu concentrations measured in 
melatonin, the treated ZL rats were significantly lower to those found in the non-treated 
ZL group (M-ZL vs. C-ZL; p < 0.05). 
Figure 2. Influence of elatonin supple entation in n levels of hite adipose tissues ( T) in
male Zücker lean and diabetic fatty rats. (A) Gonadal WAT Zn. (B) Renal WAT Zn. (C) Omentum
WAT Zn. (D) Subcutaneous Zn. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with
melatonin; C–ZDF: Control diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with
melatonin; ZL: Zücker lean rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of
ratios of Zn levels. * p < 0.05; ** p < 0.01; *** p < 0.001 (Tukey post hoc test).
For Zn, in ZDF rats, the supplementation with melatonin significantly increased the
concentrations in skeletal muscle (C–ZDF vs. M–ZDF; Figure 1B; p < 0.05) and perirenal
WAT (Figure 2B; p < 0.01). Additionally, in ZL rats, melatonin supplementation significantly
enhanced Zn concentrations in the liver (C–ZL vs. M–ZL; Figure 1A; p < 0.001).
For perirenal WAT (Figure 2B) and brain (Figure 1D) Zn levels measured in ZDF rats
treated with melatonin were significantly higher than those measured in both ZL rat groups
(M–ZDF vs. C–ZL group, p < 0.05 for both organs; M–ZDF vs. M–ZL group, p < 0.001 and
p < 0.01, respectively). Moreover, Zn concentrations found in omentum WAT (Figure 2C)
for ZDF rats treated with melatonin were significantly higher than those measured for ZL
rats also treated with melatonin (M–ZL vs. M–ZDF group; p < 0.05; Figure 2C). Another
striking finding is that from the eight analyzed tissues, for five (liver, pancreas, brain, and
perirenal and subcutaneous lumbar WAT), significantly higher Zn concentrations were
measured in the melatonin-treated ZDF rats when compared with those found in non-
treated ZL rats (M–ZDF vs. C–ZL; p < 0.001 for liver and p < 0.05 for the remaining reported
tissues). Moreover, Zn concentrations found in the brain (Figure 1D), and perirenal and
omentum WAT (Figure 2B,C, respectively) for melatonin-treated ZDF were significantly
higher than those found for melatonin-treated ZL rats (M–ZL vs. M–ZDF group; p < 0.01,
p < 0.001, and p < 0.05, respectively).
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Figures 3 and 4 depict the Cu concentrations, respectively, measured in the same
organs (Figure 3A–D, respectively) and WAT (Figure 4A–D, respectively) from the same
animal groups. The Cu concentrations did not significantly differ between C–ZL and
C–ZDF rats for any of the several studied tissues, indicating that element concentrations in
them are not significantly influenced by the obesity and T2DM pathologies.




Figure 3. Influence of melatonin supplementation in Cu levels of different organ tissues in male 
Zücker lean and diabetic fatty rats. (A) Liver Cu. (B) Skeletal muscle Cu. (C) Pancreas Cu. (D) Brain 
Cu. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with melatonin; C–ZDF: Control 
diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with melatonin; ZL: Zücker lean 
rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of ratios of Zn levels. * p < 
0.05; ** p < 0.01; *** p < 0.001 (Tukey post hoc test). 
Figure 3. Influence of melatonin supplementation in Cu levels of different organ tissues in male
Zücker lean and diabetic fatty rats. (A) Liver Cu. (B) Skeletal muscle Cu. (C) Pancreas Cu. (D) Brain
Cu. C–ZL: Control lean rats without melatonin; M–ZL: Lean rats with melatonin; C–ZDF: Control
diabetic fatty rats without melatonin; M–ZDF: Diabetic fatty rats with melatonin; ZL: Zücker lean
rats; ZDF: Zücker diabetic fatty rats. Values are means ± SEM (n = 10) of ratios of Zn levels. * p < 0.05;
** p < 0.01; *** p < 0.001 (Tukey post hoc test).
For Cu, in ZDF rats, the supplementation with melatonin significantly increased con-
centrations only in the muscle (C–ZDF vs. M–ZDF; Figure 3B; p < 0.05). In addition, in the
liver for both groups of ZDF rats significantly higher Cu concentrations than those mea-
sured in melatonin-treated ZL rats were found (M–ZL vs. C–ZDF and M–ZDF; Figure 3A;
p < 0.001 and p < 0.01, respectively). Moreover, in the liver Cu concentrations measured in
melatonin, the treated ZL rats were significantly lower to those found in the non-treated
ZL group (M–ZL vs. C–ZL; p < 0.05).
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Figure 4. Influence of melatonin supplementation in Cu levels of different white adipose tissues 
(WAT) in male Zücker lean and diabetic fatty rats. (A) Gonadal WAT Cu. (B) Renal WAT Cu. (C) 
Omentum WAT Cu. (D) Subcutaneous Cun. C–ZL: Control lean rats without melatonin; M–ZL: 
Lean rats with melatonin; C–ZDF: Control diabetic fatty rats without melatonin; M–ZDF: Diabetic 
fatty rats with melatonin; ZL: Zücker lean rats; ZDF: Zücker diabetic fatty rats. Values are means ± 
SEM (n = 10) of ratios of Zn levels (p > 0.05; Tukey post hoc test). 
4. Discussion 
In the present study, we found that Zn and Cu concentrations in the analyzed tissues 
were not affected by obesity and T2DM. This finding indicates the lack of influence of the 
aforementioned pathologies on the tissue homeostasis of these minerals in the animal 
model of diabesity ZDF rats. Similarly, other authors [39] did not find differences on Zn 
levels measured in the liver of ZL and ZDF groups. However, they reported that Zücker 
obese rats had a reduction in the Zn and Cu concentrations presumably as a result of the 
increased fat content in the liver of these obese rats. 
Melatonin supplementation did not change the Cu levels in several peripheral organs 
as well as the internal and lumbar subcutaneous WAT studied, in contrast to that reported 
by other authors [19,40,41]. In the same way, our results did not agree with those reported 
by Zhou et al. [20] on the enhancement of renal and serum Cu levels and the decrease of 
hepatic Cu and Zn levels at 2 weeks and 2 months, respectively, after the diabetes onset, 
as it is induced by the streptozotozin T1DM phenotype. 
In the present study, we have shown that melatonin supplementation in the diabesity 
animal model studied, increased Zn levels only in skeletal muscle (p < 0.05), as shown by 
comparing levels between the control group (C-ZDF) and those of the melatonin-treated 
group (M-ZDF). 
It has been reported that Zn supplementation increased insulin receptor tyrosine 
phosphorylation, Akt phosphorylation, and GLUT4 translocation in skeletal muscle cells 
[16,42,43], which subsequently increases the uptake of glucose [10,44]. Our findings are 
encouraging, in the search for new classical therapeutic alternatives, given that melatonin 
supplementation specifically increases Zn levels in skeletal muscle, which given its 
Figure 4. Influence of melatonin supplementation in Cu levels of different white adipose tissues
(WAT) in male Zücker lean and diabetic fatty rats. (A) Gonadal WAT Cu. (B) Renal WAT Cu.
(C) Omentum WAT Cu. (D) Subcutaneous Cun. C–ZL: Control lean rats without melatonin; M–ZL:
Lean rats with melatonin; C–ZDF: Control diabetic fatty rats without melatonin; M–ZDF: Dia-
betic fatty rats with melatonin; ZL: Zücker lean rats; ZDF: Zücker diabetic fatty rats. Values are
means ± SEM (n = 10) of ratios of Zn levels (p > 0.05; Tukey post hoc test).
4. Discussion
In the present study, we found that Zn and Cu concentrations in the analyzed tissues
were not affected by obesity and T2DM. This finding indicates the lack of influence of
the aforementioned pathologies on the tissue homeostasis of these minerals in the animal
model of diabesity ZDF rats. Similarly, other authors [39] did not find differences on Zn
levels measured in the liver of ZL and ZDF groups. However, they reported that Zücker
obese rats had a reduction in the Zn and Cu concentrations presumably as a result of the
increased fat content in the liver of these obese rats.
Melatonin sup lementation did not change the Cu levels in several peripheral organs
as well as the internal and lumbar subcutaneous WAT studied, in contrast to that reported
by other authors [19,40,41]. In the same way, our results did not agre with those reported
by Zhou et al. [20] on the enhancement of renal and serum Cu levels and the decrease of
hepatic Cu and Zn levels at 2 weeks and 2 months, respectively, after he diabetes onset, as
it is induced by the strep ozotozin T1DM phenotype.
In the present study, we have shown that melatonin sup lementation in the diabesity
animal model studied, increased Zn levels only in skeletal muscle (p < 0.05), as shown by
comparing levels betwe n the control group (C–ZDF) and those of the melatonin-treated
group (M–ZDF).
It has been reported tha Zn supplementation increased insulin receptor tyrosine phos-
phorylati n, Akt phosphorylation, and GLUT4 translocation in skeletal muscle ce ls [16,42,43],
which subsequently incr ases the uptake of glucose [10,44]. O r findings are encouraging, in
the search for new classical therapeutic alternatives, given that melatonin supplement tion
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specifically increases Zn levels in skeletal muscle, which given its insulin-mimetic charac-
ter [15,45], would allow acting in the regulation of blood glucose levels in this pathology,
through the activation of other Zn-dependent signaling pathways in skeletal muscle. It is also
known that 60% of the total body Zn pool is in skeletal muscle [44]. Future studies should
investigate whether the increase in skeletal muscle Zn following melatonin supplementation
in ZDF rats is specifically established in the cytoplasm with the intervention of multiple Zn
Zip transporters (1–6, 8, 10, and 14) [14,15] located in the cell plasma membrane and/or
in the cytoplasmic organelles where Zip7 is located [14]. Therefore, future research should
implement studies of the subcellular and compartmental levels of Zn in skeletal muscle fol-
lowing melatonin administration in ZDF rats. In this sense, some authors have described that
overexpression of Zip7 in C2C12 cells induced multiple genes related to glucose metabolism
in skeletal muscle cells, including GLUT4, Irs1 (insulin receptor substrate-1), and Irs2 [16],
acting in an insulin-like manner and ultimately activating glucose uptake [46].
Therefore, future studies should determine the possible connection between melatonin
supplementation, increased Zn levels in skeletal muscle, and the possible upregulation of
the downregulated Zip-Zn transporters in this animal model of obesity and T2DM.
Previous studies performed by our research group have shown that melatonin sup-
plementation (10 mg/kg/day) in the same strain model of diabesity (ZDF rats) improved
blood parameters related to glucose tolerance and insulin resistance, such as fasting blood
glucose, insulin, insulin resistance index such as HOMA-IR, HOMA1-%B of the β-cell
function and adiponectin levels, as well as leptin concentrations [10]. One of the possible
signaling pathways through which melatonin could exert such an effect in the ZDF rats
would be that of increased Zn levels in skeletal muscle found in the present study, with
the possible involvement of the cell plasma membrane Zip transporters (1–6, 8, 10, and 14)
and/or Zip7 endoplasmic reticulum. In line with this, the insulin-mimetic action of Zn is
known to act at two levels such as inactivation of the negative regulator of insulin signaling,
protein tyrosine phosphatase (PTP1B) through direct binding of this enzyme [47] and that
of protein kinase B (Akt) phosphorylation, which ultimately facilitates the mobilization of
the glucose transporter GLUT4 to the plasma membrane with subsequent translocation
of glucose into the cytosol [14,15]. In this sense, 20 µM ZnSO4 supplementation induced
glucose oxidation in both mouse and human skeletal muscle cells compared with the un-
treated control [15]. The current study demonstrates a reinforcement of the aforementioned
decrease in insulin resistance [48] through another additional signaling pathway such as
elevated muscle Zn levels, implying finally the possible existence of two complementary
pathways in the improvement of hyperglycaemia.
Other studies have reported that melatonin supplementation stimulated SOD1 in
coronary artery disease [49,50] or upregulated the SOD1 to deal with the neuronal dam-
age caused by enhanced oxidative stress induced by PCBs in adult rats [51]. Other re-
searchers [52] stated that in patients with unstable angina, there are diminished serum
levels of 6-sulfatoxy melatonin and SOD1 associated with an increase of oxidized-LDL
levels as a first step to the atherosclerotic process. In addition, we have hypothesized that
SOD1 activation may be mediated by the rise in muscle Zn and Cu levels observed in this
study following melatonin administration in ZDF rats. Moreover, in human T2DM pa-
tients, a low expression of antioxidant enzymes such as SOD1 has been observed given the
excessive glycation that sets in [53]. Extracellular SOD3 expression has also been shown to
be reduced with the increased production of the superoxide radical (O2-•) associated with
the decreased expression of the Cu transporter protein ATP7A, in blood vessels from mice
with T1DM and T2DM [54], as well as in patients and those from high-fat-diet-induced
T2DM [55]. In the present study, the increased Zn and Cu levels established by melatonin
supplementation in muscle in ZDF rats could also be related to the increased Zn, Cu-SOD
activity observed after melatonin supplementation in previous studies [17,23,24]. In this
regard, melatonin supplementation in these ZDF rats has been shown to lower basal and
Fe2+/H2O2-induced plasma lipid peroxidation by improving low-grade inflammation and
oxidative stress in this animal model of obesity and T2DM [31], which could be related to
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an increase in Zn, Cu-SOD activity in skeletal muscle, which is primarily responsible for
the uptake and expenditure of most blood glucose.
Other researchers reported that melatonin administered in vivo increased the expres-
sion of multiple oxidative stress regulatory enzyme genes in neuronal tissue, such as SOD1
and SOD2 [50,56], as well as SOD and glutathione peroxidase (GSH-Px) [57]. Additionally,
Mauriz et al. [58] have pointed out a potential beneficial effect of melatonin supplementa-
tion in terms of slowing aging, as they have found that this indolamine supplementation
attenuated in rat liver the downregulation in gene expression of SOD1 and cytoplasmic
and mitochondrial glutathione peroxidase that occurs with aging. Despite this, and taking
into account the role of Zn and Cu as enzyme cofactors of the SOD1 enzyme, in the present
study we did not find that melatonin supplementation in ZDF rats modified brain and
liver levels of either Zn or Cu (p > 0.05).
In the present study, melatonin supplementation in ZDF rats did not change the
pancreatic Zn levels. For this reason, as indicated above, the improvement in T2DM in ZDF
rats may have been due to the pathway previously described, which facilitated the increase
in muscle glucose uptake by activation of Akt kinase phosphorylation, and the decrease
in insulin resistance, as the enhancement in muscle Zn inhibited the negative regulator of
the insulin receptor substrate, PTP1B, in accordance with what was established by other
authors [14,15].
Of all the internal and lumbar subcutaneous WAT studied, only in the perirenal one
melatonin supplementation increased Zn levels in this diabesity animal model with respect
to the non-supplemented group (M–ZDF vs. C–ZDF; p < 0.01). Moreover, in the same
animal model, we previously found that melatonin increased Ca levels in the perirenal
WAT, etc. [50]. We do not know why this increase exclusively occurred in the perirenal
WAT and did not in the remaining internal and lumbar subcutaneous WAT. Therefore,
future studies are needed to find out which mechanism may be involved in this specific
effect of melatonin. Whether a dormant BAT exists in the perirenal adipose tissue of ZDF
rats, and if so, whether melatonin supplementation influences the activity of the SOD1
enzyme, one of whose enzyme cofactors is Zn, should also be studied in the future. In this
diabesity animal model, previous studies already showed that melatonin supplementation
increased the UCP1 protein expression in beige inguinal adipose tissues [59,60]. However,
in the present study, melatonin supplementation did not change the Cu levels in perirenal
WAT, a mineral that, similar to Zn, is also a cofactor of the SOD1 enzyme. On the other
hand, future studies should investigate whether the increase in Zn levels after melatonin
supplementation exclusively in the perirenal WAT in this diabesity animal model could
be related to a higher expression of ZFP407 or even zinc-2-glycoprotein (ZAG) in the
adipocytes of this WAT, whose expression is clearly reduced in adipose tissues, mainly in
the subcutaneous tissue, in the pathologies of obesity [61].
A striking finding of this research is that Zn levels were increased in the melatonin-
treated ZDF group with respect to the non-treated ZL one (M–ZDF vs. C–ZL), in three
of the four organs analyzed (liver, pancreas, and brain), as well as in two of the four
WAT studied namely perirenal and subcutaneous lumbar WAT. We hypothesized that
with melatonin administration in ZDF rats (M–ZDF), and in comparison with control ZL
ones (C–ZL), the oxidative stress associated with obesity and T2DM in the former was
clearly increased [40]. This effect was not established in the non-melatonin-treated control
ZL group. Therefore, we hypothesize that probably there was an increase in tissue Zn
levels in M–ZDF, as a compensatory mechanism for this oxidative stress with a consequent
increase in the expression of the cytoplasmic SOD1 enzyme. However, in future studies,
it would be necessary to compare the activity and level of Zn, Cu-SOD enzyme in the
studied tissues (liver, pancreas, brain, and in the perirenal and subcutaneous lumbar
WAT) of the two groups of animals referred to (C–ZL and M–ZDF), in order to verify the
aforementioned hypothesis.
In the present study, we have observed that melatonin administration only increased
Cu levels in muscle tissue in ZDF rats. On the other hand, it is known that ATP7A as a
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transporter for extracellular SOD3 in vascular smooth muscle, is markedly downregulated
in vessels from T2DM patients as well as those from fat-diet-induced or db/db T2DM [55] or
T1DM mice [54]. In diabetes mellitus, Akt2 is downregulated. Moreover, these researchers
reported that insulin stimulates Akt2 binding ATP7A, which next activates SOD3 by Cu [55].
Both the increased secretion of SOD3 and the translocation of the ATP7A transporter to the
plasma membrane of the arterial endothelial cell will ultimately allow the active SOD3 to
neutralize the O2-• radical allowing NO to act on the arterial endothelium, finally relaxing
it [54,55]. Therefore, this prevents the problems of atherosclerosis and cardiovascular
disease, in general, associated with DM. Moreover, in the present study, as we have pointed
out previously, an increase in the muscle level of Zn, whose insulin-mimetic action is
mediated by its transporters such as Zip (1–6, 8, 10, and 14) [14] located in the plasma
membrane or Zip7 mainly located in the membrane of the endoplasmic reticulum and
the Golgi apparatus occurred [14]. Therefore, a possible explanation, which would have
to be checked in future studies, is that the increase at the cytoplasmic level of Zn in the
muscle cell could activate Akt2. Therefore, the whole mechanism of action referred above
of enhancing and restoring Akt2-ATP7A-SOD3 pathways, could be related to the present
findings of increased muscle Cu and Zn levels after melatonin supplementation in this
animal model of obesity and T2DM.
Nevertheless, the design of this study has two main limitations: First, we did not
measure insulin resistance. However, in a previous study, we measured insulin resistance
and glucose homeostasis in the same animal model of diabesity [10]. Second, the hypothe-
ses for SOD1 have not been measured in the analyzed tissues. Although, we previously
measured this enzyme activity in renal tissue [20], finding that melatonin-supplemented
rats showed greater SOD activity in renal mitochondria of lean and diabetic obese ones. On
the other hand, in the study design, we used a daily dose of melatonin of 10 mg/kg body
weight. These limitations as well as a possible more appropriate melatonin dose should be
considered in the design of future studies on this subject.
5. Conclusions
This is the first study to demonstrate that chronic melatonin supplementation in the
animal model of obesity and the associated T2DM represented by ZDF rats increased
Zn and Cu levels in skeletal muscle cells. This, at least partially, and in concert with
our previously reported antihyperglycemic and antihyperinsulinemic effects in the same
strain animal model, support that melatonin supplementation improves conditions of
diabetes associated to obesity. Further in vitro and/or in vivo studies are required to fully
understand the possible effect of melatonin through Zn and Cu levels overall in skeletal
muscle in obesity associated diabetes, as well as decipher the precise underlying related
molecular mechanism.
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